Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981842 | 0.88 | TSHR (0.42) | NPC1RAB9AMEN1KMT2AGRM5 | |
| SCHEMBL12076675 | 0.83 | CYP1A2 (0.47) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL2992434 | 0.81 | HPGD (0.38) | NPC1RAB9AMEN1KMT2ACASP3 | |
| SCHEMBL2985650 | 0.75 | PTGS2 (0.48) | KMT2AMAPTPTGS2KDM4E | |
| SCHEMBL22214581 | 0.75 | MAPT (0.38) | NPC1RAB9ASMN1; SMN2HPGDNFKB1 | |
| SCHEMBL16005725 | 0.74 | ALDH1A1 (0.41) | NPC1RAB9AMEN1KMT2ACYP1A2 | |
| SCHEMBL2994740 | 0.73 | FDPS (0.40) | NPC1RAB9AMEN1KMT2ACYP1A2 | |
| SCHEMBL4148824 | 0.72 | EGFR (0.46) | RAB9AMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL2987944 | 0.72 | KDM4E (0.45) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4140780 | 0.71 | ALDH1A1 (0.43) | MEN1KMT2ACYP1A2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | claimed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | NPC1 26/4885RAB9A 446/4885MEN1 3980/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | NPC1 138/4885RAB9A 3156/4885MEN1 3473/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | NPC1 412/4885RAB9A 3991/4885MEN1 4030/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | NPC1 504/4885RAB9A 3015/4885MEN1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.